Recent blog posts
Latest Hotspot
3 min read
FDA approves Tarsus new drug Xdemvy for the treatment of demodex blepharitis
28 July 2023
On July 26, 2023, Tarsus Pharmaceuticals announced that the U.S. FDA has approved Xdemvy (lotilaner ophthalmic solution, 0.25%) for the treatment of Demodex blepharitis.
Latest Hotspot
2 min read
Boehringer Ingelheim & Eli Lilly's SGLT2 inhibitor Empagliflozin obtains new indication approval in the European Union
27 July 2023
Empagliflozin is the first Sodium-Glucose Co-Transporter-2 (SGLT2) inhibitor to statistically significantly reduce the risk of hospitalization for any cause compared to a placebo in patients with CKD.
Latest Hotspot
2 min read
CanSino's Herpes Zoster vaccine CS-2032 has been approved for clinical use in Canada
26 July 2023
On July 23, CanSino Biologics announced that its recombinant shingles vaccine CS-2032, developed in collaboration with Vaccitech, has received clinical trial approval from Health Canada.
Latest Hotspot
3 min read
Roche introduces Alnylam's hypertension RNAi therapy, Zilebesiran, with a potential transaction value of up to 2.8 billion dollars
26 July 2023
On July 24, 2023, Alnylam announced that it has reached a strategic agreement with Roche to develop and commercialize Zilebesiran, Alnylam's RNAi therapeutic drug for the treatment of hypertension.